April 16, 2026
Sanity Group
Organigram Global and Sanity Group Announce Successful Closing of Acquisition
Unlocking the health benefits of cannabinoids
What we do
Sanity Group is one of Europe’s leading cannabis companies. The group brings together its own brands and businesses across medical cannabis, research on finished cannabis pharmaceuticals, cosmetics, wellbeing and lifestyle. In addition, Sanity Group is involved in scientific pilot projects on recreational cannabis within a legalized setting.
Our brands
An overview of our brands in medical cannabis, scientific pilot projects on recreational cannabis and CBD products.
ZOIKS - aims to improve patient care with high-quality medicinal cannabis through particularly affordable medicines.
avaay Medical supplies patients through pharmacies with high-quality cannabis medicines - for a individualized therapy with natural products.
Vayamed is a fully licensed pharmaceutical company that distributes medical cannabis medicines to pharmacies and clinical facilities - focusing on the supply to patients with statutory health insurance.
Grashaus Projects is an official pilot project for recreational cannabis in Switzerland, investigating the effects of the legal sale of THC-containing products on the consumption behaviour of study participants.
vaay positions itself as the "wellbeing brand" of the Sanity Group, focusing on CBD products in the fields of cosmetics, dietary supplements, and lifestyle.
Status quo of our industry
Against the backdrop of the ongoing legalisation and acceptance of cannabis in North America and worldwide, both for medical and recreational purposes, Europe is going its own way. With over 700 million inhabitants in continental Europe and 500 million within the EU, the European cannabis market is estimated to be worth more than €100 billion by 2028.
Originating in Europe's largest cannabis market – Germany – the Sanity Group has specialised in the complex regulations and requirements surrounding cannabis since its inception in order to further explore the plant's potential and make it accessible in a controlled manner.
Latest News
April 1, 2026
Sanity Group
Evaluation Report on Second Anniversary of German Cannabis Act: Sanity Group Calls for Evidence-Based Regulation
March 23, 2026
Sanity Group
Sanity Group and Curaleaf Laboratories Announce Partnership to Advance Medical Cannabis Innovation in the UK
February 18, 2026
Sanity Group
Sanity Group Becomes Part of Canadian Cannabis Market Leader Organigram Global to Drive International Growth
February 8, 2026
Sanity Group
Two Years of Legal Cannabis from Specialized Retail Stores: Swiss Pilot Project Shows Positive Effects on Health Protection, Consumer Competence, and ...